Clinical Trials Logo
  1. Home
  2. Early-Stage Breast Carcinoma
  3. NCT02947425

TARGeted Intraoperative radioTherapy (TARGIT) Registry Database — TARGIT R  

Early-Stage Breast Carcinoma Clinical Trial

Official title:
TARGIT R: TARGeted Intraoperative radioTherapy (TARGIT) Registry Database

Clinical Trial Summary

This is a prospectively registered database of patients with early breast cancer who will be treated with radiotherapy during surgery. More than 2000 women have already received this treatment in clinical trials. This study will monitor the health status of women who receive this treatment outside of a clinical trial, especially those who might not have been eligible for the original clinical trials. The aim is to confirm the long-term effectiveness and safety of the technique.

Clinical Trial Description

Registration of patients selected for this treatment; collecting data regarding safety and toxicity on patients who have had treatment with TARGIT.

Outcomes will be measured over short and long terms. Outcome measures will include effectiveness and safety, assessed in various cohorts of patients. Core outcomes will be used for effectiveness. In addition, true recurrence (basically, ipsilateral breast tumor recurrence at the same site as the original primary) will be used as defined by Recht. Safety outcomes will be based on Common Toxicity Criteria.

Budget impact analysis of IORT in subgroups of patients will be assessed. This amounts to using cost data to calculate the mean incremental (or extra) cost per person treated using intraoperative radiotherapy (IORT) versus external beam radiotherapy (EBRT) and mastectomies (where IORT could have been given instead) and then multiplying this by the total patients eligible nationally for IORT, to calculate the total expected budget impact on the NHS if IORT in these subgroups was rolled out nationally. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02947425
Study type Observational [Patient Registry]
Source University College, London
Contact Nick J Roberts
Email SITU.TARGITR@ucl.ac.uk
Status Recruiting
Phase
Start date July 2013
Completion date July 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04290897 - Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors Phase 2
Active, not recruiting NCT02592083 - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors Phase 2
Active, not recruiting NCT02568839 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer Phase 2/Phase 3
Completed NCT02481128 - Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer N/A
Active, not recruiting NCT03077841 - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Phase 2/Phase 3
Completed NCT02310984 - PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional N/A
Recruiting NCT02511301 - Circadian Thermal Sensing to Detect Breast Disease Phase 1/Phase 2
Active, not recruiting NCT02474641 - Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer N/A
Withdrawn NCT04560439 - Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors N/A
Completed NCT02129686 - A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients N/A
Completed NCT02806817 - ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism Early Phase 1
Active, not recruiting NCT02603679 - Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases Phase 2
Active, not recruiting NCT03025139 - Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) N/A
Completed NCT04081389 - Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Phase 1
Completed NCT02441946 - A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Phase 2
Completed NCT04294225 - Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer Phase 2